GT Biopharma logo
GT Biopharma GTBP
$ 2.93 -7.86%
report update icon

Quarterly report 2026-Q3
added 11-16-2026

GT Biopharma Revenue | GTBP

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue GT Biopharma

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
- - - - - - - - - - 27 K 61 K 368 K 342 K 26 K - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
368 K 26 K 165 K

Quarterly Revenue GT Biopharma

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 20 K 7 K - 3 K 25 K - - 183 K 56 K 88 K - 120 K 1 K 1 K - 2 K 1 K 20 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
183 K 1 K 40.5 K

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
7.7 M $ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.26 M - 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
29.4 B $ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
72.3 M $ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
277 M - - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
30.8 M - -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
1.04 M - -33.86 % $ 61.2 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
3 M - -14.27 % $ 1.7 M singaporeSingapore
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1 M - - $ 86.2 M usaUSA
BELLUS Health BELLUS Health
BLU
16 K - - $ 2.47 B canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
199 M - - $ 13.6 B usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
31 M - - $ 29.6 M usaUSA
GeoVax Labs GeoVax Labs
GOVX
2.49 M $ 1.83 -4.45 % $ 8.35 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
236 K - -33.41 % $ 3.37 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
654 K - - $ 12.2 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
234 M - - $ 309 M usaUSA
Aptinyx Aptinyx
APTX
1 M - -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
12 M - -1.38 % $ 46.8 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
1.25 B - -0.75 % $ 18.7 M danmarkDanmark
9 Meters Biopharma 9 Meters Biopharma
NMTR
1.88 M - -42.97 % $ 1.05 M usaUSA
Theratechnologies Theratechnologies
THTX
85.9 M - - $ 83.9 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
178 M - -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
734 K - -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
22.9 M - -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
41.2 M - - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
160 M - - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
17.6 M - - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
2.07 M $ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
2.2 M - -47.76 % $ 6.27 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
517 M - - - russiaRussia
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
163 M - - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
2.07 M - - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
16.3 M - 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
3.09 M - 17.91 % $ 11.1 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
184 K - -3.76 % $ 3.47 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
43.9 M - -6.92 % $ 79.4 M usaUSA
Otonomy Otonomy
OTIC
125 K - -1.96 % $ 4.68 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
268 M $ 286.96 0.01 % $ 5.55 B usaUSA
Фармсинтез Фармсинтез
LIFE
372 M - - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
90 K $ 1.04 -4.59 % $ 32.4 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
785 K - -24.12 % $ 1.56 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
325 K - - $ 26.5 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
32.6 M - - $ 401 M usaUSA
Histogen Histogen
HSTO
3.77 M - 31.6 % $ 2.12 M usaUSA